INTRODUCTION {#s1}
============

The c-Met tyrosine kinase receptor (TKR), upon activation by its cognate antigen, hepatocyte growth factor (HGF), generates proliferation, migration, and survival signals in numerous cancers\[[@R1], [@R2]\]. This signaling cascade parallels, and at times can supplement, the activity of other oncogenic TKRs. As a result, the c-Met pathway has emerged as a resistance pathway in therapies targeting the epidermal growth factor receptor (EGFR)\[[@R3], [@R4]\], B-Raf\[[@R5]\], and vascular endothelial growth factor receptor (VEGFR)\[[@R6]\], among others. Various *MET* alterations, including amplification and nucleotide variations, have been described and are associated with resistance to therapy and aggressive clinical behavior\[[@R3], [@R4], [@R7]\]. The pathologic implications of this important receptor has prompted the development of c-Met inhibitors, many of which are currently undergoing early phase trials in various cancers\[[@R2]\].

Ovarian, primary peritoneal, and fallopian tube cancers have similar ontological origins and clinical presentations. Their aggressive metastatic behavior and generally poor prognosis has prompted interest in developing therapies with TKR inhibitors, including those targeting EGFR and c-Met\[[@R8], [@R9]\]. However, outside of bevacizumab, targeted therapies tested in early clinical trials have yet to gain widespread clinical success\[[@R8]\]. Despite understanding of the intrinsic biology of the c-Met pathway and its documented role in drug resistance, no substantive clinical series have assessed the effect of *MET* variations and amplifications in this disease\[[@R10]-[@R12]\]. We, therefore, investigated the clinical and molecular characteristics of patients with ovarian cancers referred to our Phase I Clinical Trials Program and their response to treatment on a phase I c-Met inhibitor trial.

RESULTS {#s2}
=======

Patient Characteristics {#s2_1}
-----------------------

One-hundred-and-seventy-eight patients met study inclusion criteria, of whom 122 and 113 were tested for *MET* variations and amplification, respectively. Fifty-seven patients were tested for both variation and amplification. *MET* nucleotide variations were detected in 9 patients (7.4%): 6 with N375S and 3 with T1010I nonsynonomous variations. *MET* amplification was detected in 4 patients (3.5%), amplification gene copy numbers (in relation to *CEP7*) were 2.12, 2.27, 2.55, and 2.78. No patients exhibited concomitant *MET* nucleotide variation and amplification.

Characteristics associated with *MET* aberrations {#s2_2}
-------------------------------------------------

No significant differences were noted between patient characteristics when stratified by *MET* variation or amplification status (all p\>0.05). *MET* variations were detected only in white women with high-grade primary ovarian tumors (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). The histology of cancers with *MET* variations was predominately serous (74%), with one patient each having carcinosarcoma and clear cell carcinoma (Table [1](#T1){ref-type="table"}). The median numbers of metastatic sites among patients with *MET* variations compared with those without were both 2. Among patients with *MET* variations, 44% had liver metastasis, a rate similar to liver metastasis in patients without *MET* variation (34%). Concomitant mutations included *KRAS*, *BRCA1*, *ARID1A,* and *TP53* were identified in 1, 1, 1, and 2 patients, respectively. In addition, one patient had concomitant PTEN loss and another had weak PTEN staining (Table [2](#T2){ref-type="table"}). Of note, no ovarian cancer patients within any stratum exhibited *ALK* rearrangement, *BRAF*, *EGFR*, or *KIT* mutations.

###### Demographic characteristics and metastatic sites in patients stratified by MET nucleotide variation and amplification status

  Characteristic                    Wild-Type (n=113)   Variation (n=9)   Not amplified (n=109)   Amplified (n=4)
  --------------------------------- ------------------- ----------------- ----------------------- -----------------
  Age Diagnosis: Median (Q3-Q1)     54 (47-61)          54 (46-56)        54 (47-61)              60 (54-67)
  Prior Therapies: Median (Q3-Q1)   3 (2-5)             3 (2-5)           3 (2-5)                 2 (1-5)
  Diagnosis                                                                                       
  Fallopian                         11 (9%)             0                 1 (1%)                  0
  Peritoneal vs. Ovarian            2 (2%)              0                 1 (1%)                  0
  Peritoneal                        5 (4%)              0                 2 (2%)                  0
  Ovarian                           95 (84%)            9 (100%)          105 (96%)               4 (100%)
  Ethnicity                                                                                       
  Asian/AM-indian                   2 (2%)              0                 2 (2%)                  0
  Black                             3 (3%)              0                 4 (4%)                  1 (25%)
  Hispanic                          11 (10%)            0                 9 (8%)                  0
  White                             97 (86%)            9 (100%)          94 (86%)                3 (75%)
  Histology                                                                                       
  Serous                            75 (66%)            7 (78%)           70 (64%)                4 (100%)
  Endometrioid                      5 (4%)              0                 5 (5%)                  0
  Clear Cell                        9 (8%)              1 (11%)           13 (12%)                0
  Mucinous                          0                   0                 2 (2%)                  0
  Mixed                             11 (10%)            0                 13 (12%)                0
  Carcinoma NOS                     2 (2%)              0                 1 (1%)                  0
  Carcinosarcoma                    5 (4%)              1 (11%)           1 (1%)                  0
  Granulosa                         6 (5%)              0                 4 (4%)                  0
  Metastasis                                                                                      
  \# Met Sites: Median (Q3-Q1)      2 (2-3)             2 (2-4)           2 (2-3)                 2 (2-3)
  Liver                             39 (34%)            4 (44%)           48 (44%)                1 (25%)
  Lungs                             23 (20%)            3 (33%)           20 (18%)                0
  Bone                              6 (5%)              0                 7 (6%)                  0
  CNS                               4 (4%)              0                 4 (4%)                  0
  Peritoneum                        102 (90%)           8 (89%)           97 (89%)                4 (100%)
  Other Sites                       83 (73%)            7 (78%)           81 (74%)                3 (75%)

Abbreviations: (Q3-Q1) = 75th to 25th percentile, AM-indian = American indian, NOS = not otherwise specified, Met = metastatic, CNS = central nervous system.

###### Histologic and genetic characteristics in patients stratified by MET nucleotide variation and amplification status

  Characteristic                                     No Variation (n=113)   Variation (n=9)   Not amplified (n=109)   Amplified (n=4)
  -------------------------------------------------- ---------------------- ----------------- ----------------------- -----------------
  HER2 amplification                                 4/73 (5%)              0/5               3/71 (4%)               0/2
  ALK rearrangement                                  0/36                   0/2               0/38                    0/1
  PIK3CA mutation                                    8/109 (7%)             0/9               10/104 (10%)            0/4
  KRAS mutation                                      11/105 (10%)           1/8 (13%)         7/90 (8%)               0/3
  EGFR mutation                                      0/86                   0/4               0/76                    0/3
  TP53 mutation[\*](#tfn_001){ref-type="table-fn"}   34/69 (49%)            3/4 (75%)         18/33 (5%)              0/1
  BRAF mutation                                      0/103                  0/8               0/82                    0/3
  NRAS mutation                                      2/96 (2%)              0/3               0/45                    0/2
  KIT mutation                                       0/83                   0/3               0/48                    0/1
  \% ER+: median (Q3-Q1)                             70 (20-90) N=86        30 (20-80) N=7    70 (5-90) N=81          35 (13-65) N=4
  \% PR+: median (Q3-Q1)                             10 (5-30) N=50         N=0               5 (1-38) N=28           3 (1-5) N=2
  PTEN                                                                                                                
  Loss                                               7/77 (9%)              1/8 (13%)         4/81 (5%)               2/4 (50%)
  Weak                                               10/77 (13%)            1/8 (13%)         15/81 (19%)             0/4
  No Loss                                            60/77 (78%)            6/8 (75%)         62/81 (77%)             2/4 (50%)
  Grade                                                                                                               
  Low                                                9/97 (9%)              0                 6/87 (7%)               0
  Medium                                             2/97 (2%)              0                 2/87 (2%)               0
  High                                               86/97 (89%)            6/6 (100%)        79/87 (91%)             4/4 (100%)
  Heredity                                                                                                            
  1st Degree                                         33/113 (29%)           2/9 (22%)         30/109 (28%)            1/4 (25%)
  2nd Degree                                         40/113 (35%)           3/9 (33%)         33/109 (30%)            2/4 (50%)
  BRCA1 or 2 mutation                                10/31 (32%)            1/2 (50%)         9/28 (32%)              0/2

Numerator within each cell indicates number of patients exhibiting the characteristic while denominator indicates number of patients tested

Abbreviations: (Q3-Q1) = 75th to 25th percentile, % ER+ = percent of cell staining positive for estrogen receptor, % PR+ = percent cells staining positive for progesterone receptor, 1st Degree = presence of any first degree relative with either breast or ovarian cancer, 2nd Degree = presence of any second degree relative with either breast or ovarian cancer

TP53 testing was conducted by hotspot analysis

*MET* amplification occurred only in women with high grade serous ovarian cancer (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). Three out of 4 women were white and 1 was black. Similar to patients with *MET* variations, *MET* amplified patients had a median of 2 metastatic sites, with 1 patient exhibiting liver metastasis. No concomitant mutations were observed in *MET* amplified patients except for in 2 patients who exhibited loss of PTEN protein expression.

*MET* alterations and survival {#s2_3}
------------------------------

OS in patients with a *MET* aberration (either variation or amplification, n=13) was compared with that of patients known to be negative for any aberrations (n=50). There was no significant different in median survival in patients exhibiting *MET* alterations (Fig. [1](#F1){ref-type="fig"}; HR=1.6, p=0.25). Patients with *MET* alterations trended towards worse OS in multivariate analysis (HR=1.8, p=0.13) when adjusting for histology (serous vs. other), age (≥60 vs. \<60), and number of prior therapies (\>3 vs. ≤3).

![Kaplan-Meier plot of overall survival in ovarian cancer patients with MET variation or amplification (dashed-black line) compared with patients without MET variation or amplification (solid-gray line)](oncoscience-01-0005-g001){#F1}

Treatment with c-Met inhibitors {#s2_4}
-------------------------------

All patients treated on a Phase I c-Met inhibitor clinical trial had a diagnosis of ovarian cancer. This included 4 patients with *MET* nucleotide variation and one with *MET* amplification (Table [3](#T3){ref-type="table"}). No patients with a *MET* alteration achieved an objective response.

###### Histology and mutation status of patients exhibiting MET variation or amplification, and their response to c-Met inhibitors

  Patient No.         Histology        Variation/Copy Number   Concomitant Mutations   Inhibitor Class   Best Response                             TTF (mo)
  ------------------- ---------------- ----------------------- ----------------------- ----------------- ----------------------------------------- ----------
  MET variation                                                                                                                                    
  1                   Serous           T1010I                  BRCA1                   c-Met specific    PD (+29)                                  1
  2                   Serous           T1010I                  \-                                        \-                                        \-
  3                   Serous           T1010I                  TP53                                      \-                                        \-
  4                   Carcinosarcoma   N375S                   \-                      c-Met specific    PD (+39)                                  1.2
  5                   Clear Cell       N375S                   PTEN loss               Multikinase       SD (+19)                                  1.2
  6                   Serous           N375S                   KRAS                    Multikinase       SD (+16)                                  1.5
  7                   Serous           N375S                   TP53                                      \-                                        \-
  8                   Serous           N375S                   \-                                        \-                                        \-
  9                   Serous           N375S                   TP53, ARID1A                              \-                                        \-
  MET amplification                                                                                                                                
  10                  Serous           2.12                    PTEN loss               Multikinase       PD([\*](#tfn_002){ref-type="table-fn"})   2.1
  11                  Serous           2.27                    PTEN loss                                 \-                                        \-
  12                  Serous           2.55                    \-                                        \-                                        \-
  13                  Serous           2.78                    \-                                        \-                                        \-

Abbreviations: PD = progressive disease, SD = stable disease, TTF = time to failure

Indicates clinical progressive disease

Among all patients with ovarian cancer treated on a c-Met inhibitor trial, 5 out of 18 (28%) exhibited a partial response (PR) or stable disease (SD) lasting ≥6 months. Of these, 2 of 18 patients (11%) achieved a best response of PR (Fig. [2](#F2){ref-type="fig"}, Table [4](#T4){ref-type="table"}). Prolonged SD lasting ≥6 months was achieved in 3 patients with TTFs lasting 6, 7.8, and 29.8 months. The median TTF in patients treated with a c-Met-specific inhibitor (1.5 months, range 0.4-7.8 months, n=9) was less than patients treated with a multikinase inhibitor (n=8) or a multikinase inhibitor combined with a VEGFR2 inhibitor (n=1)(4.5 months, range 1.2-29.8 months). This difference trended towards significance (p=0.07). Interestingly, among 3 patients with known *TP53* mutations treated on a c-Met inhibitor trial, the 2 patients treated with a c-Met inhibitor with multikinase activity exhibited objective responses, while the one patient who was treated with a c-Met specific inhibitor did not (Table [4](#T4){ref-type="table"}).

![Waterfall graph of ovarian cancer patients treated on a c-Met inhibitor Phase I trial with measurable disease by RECIST criteria\
Patients exhibiting *MET* alteration are annotated above the bar with the corresponding variation or fold-amplification (in relation to *CEP7*). Patients treated with a c-Met inhibitor with multikinase activity are displayed with grey bars, while those treated with a c-Met specific inhibitor are displayed with black bars. X-axis indicates time-to-failure (months). (\*) Indicates clinically progressive disease.](oncoscience-01-0005-g002){#F2}

###### Histology, mutation status, and response of ovarian cancer patients treated on a phase I c-Met inhibitor trial

  Patient No.   Histology                    MET Variation/Amp   Other Mutations   Inhibitor Class      Best Response                              TTF (mo)
  ------------- ---------------------------- ------------------- ----------------- -------------------- ------------------------------------------ ----------------------------------------
  1             Serous                       Amp-                TP53              Multikinase          PR (−72)                                   14
  2             Endometroid                  Var−/Amp−           PI3KCA, STK11     Multikinase+VEGFR2   PR (−31)                                   7[\*\*](#tfn_004){ref-type="table-fn"}
  3             Serous                       Var−/Amp−           TP53              Multikinase          SD (−22)                                   29.8
  4             Clear Cell                   Var−                \-                c-Met specific       SD (0)                                     4.1
  5             Clear Cell                   Amp−                HER2 amp          c-Met specific       SD (0)                                     7.8
  6             Serous                       Amp−                \-                Multikinase          SD (+7)                                    6
  7             Serous                       Var−/Amp−           KRAS, TP53        c-Met specific       SD (+12)                                   2.9
  8             Serous                       N375S/Amp−          KRAS              c-Met specific       SD (+16)                                   1.5
  9             Clear Cell                   N375S/Amp−          PTEN loss         Multikinase          SD (+19)                                   1.2
  10            Serous                       Amp−                \-                c-Met specific       PD (+20)                                   1.5
  11            Mixed: Serous/Transitional   Amp−                PI3KCA            Multikinase          PD (+20)                                   2.1
  12            Mixed: Serous/Epithelial     Amp−                \-                c-Met specific       PD ([\*](#tfn_003){ref-type="table-fn"})   2.1
  13            Serous                       2.18                PTEN loss         Multikinase          PD ([\*](#tfn_003){ref-type="table-fn"})   2.1
  14            Serous                       Var−                \-                c-Met specific       PD ([\*](#tfn_003){ref-type="table-fn"})   0.5
  15            Serous                       Amp−                \-                Multikinase          PD (+26)                                   3
  16            Serous                       T1010I/Amp−         BRCA1             c-Met specific       PD (+29)                                   1.0
  17            Serous                       Amp−                \-                Multikinase          PD (+30)                                   1.2
  18            Carcinosarcoma               N375S               \-                c-Met specific       PD (+39)                                   1.2

Abbreviations: AMP = amplified, Amp− = tested, no MET amplification, Var = variation, Var− = tested, no MET nucleotide variation, PD = progressive disease, SD= stable disease, amp=amplification, TTF=time-to-failure

Indicates clinical progressive disease

Indicates continuation on a c-Met trial

DISCUSSION {#s3}
==========

The literature delineating the prevalence of *MET* amplification and variations in ovarian cancer is sparse. Yamato et al. reported on 5 patients, all with clear cell histology, identified with *MET* amplification out of 195 (2.5%) patients tested\[[@R13]\]. An earlier report using Southern blot analysis in 67 patients with ovarian cancer found no amplifications\[[@R12]\]. Two other series with 24 and 65 ovarian cancer patients found the incidence of *MET* variations to be 1 and 0, respectively \[[@R10], [@R11]\]. The rates in our current cohort (nucleotide variations, 7.4%; and amplification, 3.5%) are comparable, albeit higher, than those reported in previous studies. A possible explanation is that our study population consisted entirely of patients with metastatic or relapsed disease, which may skew in favor of increased rates of *MET* aberrations. Of note, we did not detect any patients with concomitant *MET* amplification and variation.

The biologic activity of the *MET* nucleotide variations identified here and even whether these specific variations represent somatic mutations or germline polymorphisms have yet to be fully elucidated\[[@R17], [@R18]\]. The role of *MET* amplification has been most extensively correlated with tumor invasion and aggressive metastatic behavior in gastrointestinal malignancies\[[@R19], [@R20]\]. With regard to *MET* variations, the N375S nonsynonmous variation occurs in the extracellular semaphorin domain, whereas the activating T1010I variation occurs in the juxtamembrane domain\[[@R7], [@R18]\]. The characteristics and clinical behavior of ovarian cancer in patients with MET variations have not been thoroughly described. However, data in renal cell and lung carcinomas suggest that somatic and germline *MET* polymorphisms may enhance c-Met TKR activity and even confer inhibitor resistance\[[@R17], [@R21]\]. This second observation is corroborated by our data, in which no patients exhibiting a *MET* alteration achieved an objective response on a c-Met phase I inhibitor trial. Another possible explanation for the lack of an observed objective response are that most patients in this study were enrolled on a Phase I dose escalation trials and may not have received an efficacious study drug dose. Few preclinical data have tested the efficacy of these inhibitors in *MET* altered patients \[[@R22]-[@R24]\] and to our knowledge no associated clinical data have been reported.

A subset of all ovarian cancer patients achieved objective responses. Patients treated with a multikinase inhibitor trended toward a longer TTF compared with those treated with c-Met-specific inhibitors (median 1.5 vs. 4.5 months, p=0.07). A possible explanation is that activity against VEGFR2, a target with known clinical efficacy in ovarian cancer\[[@R14]\], may increase therapeutic efficacy. Interestingly 2 out of 3 patients exhibiting *TP53* mutations exhibited objective responses to c-Met inhibitors and were both treated using a multikinase inhibitor. As such, observed responses may be due to effects on targets other than c-Met, including VEGFR2. This hypothesis is supported by recent evidence from our group showing that *TP53* mutations predict responses to anti-VEGFR2 therapies\[[@R25]\]. In addition, these data also suggests that c-Met inhibition may be more clinically efficacious when utilized in a supporting role to block resistance pathways in other targeted agents rather than being utilized alone\[[@R1], [@R2], [@R4]\]. These data are preliminary findings that warrant further investigation in a randomized clinical trial setting.

We observed no difference in survival in patients with a *MET* alteration versus those without, although in multivariate analysis patients with *MET* alterations trending towards a worse OS (HR=1.8, p=0.13). However it is possible that separate analyses of *MET* variations and amplifications may yield different results. Due to the limited incidence, we did not observe any significant differences in the characteristics of patients with *MET* alterations. In addition, a number of concomitant mutations were identified in patients harboring *MET* variations, whereas there were none in patients with *MET* amplification other than PTEN loss.

Outside of limitations inherent to all retrospective reviews, the low frequency of *MET* variations and amplifications observed in this study did not provide sufficient statistical power to stringently assess demographic and patient characteristic differences. *MET* variation testing was also done with some heterogeneity. Although the majority of patients were tested at MD Anderson core laboratories, a minority was tested with outside platforms. In addition, mutations and amplifications were often grouped within a single stratum. With regard to amplifications, the relatively low gene copy numbers found in this study (range 2.12-2.78) may be inadequate to exhibit biological differences. Finally, the few number of patients, especially *MET* altered patients, treated on c-Met inhibitor phase I trials makes generalizing these observations into a larger patient populations difficult. However, despite these limitations, to our knowledge this is one of the first studies to substantially compare the demographic and clinical characteristics of ovarian cancer patients with *MET* altered patients and their response to treatment with c-Met inhibitors. The findings of this analysis provide insight into the clinical characteristics associated with *MET* alterations and, if validated in the prospective setting, may lead to improved strategies utilizing c-Met therapies in this prognostically poor patient population.

METHODS {#s4}
=======

Patients {#s4_1}
--------

We retrospectively reviewed the medical records of all consecutive patients presenting to our Phase I Clinic starting in May 2010 to November 2012 (n=3607). Patients presented for treatment of recurrent or metastatic disease, usually after multiple prior treatments (range 0-13). Eligibility criteria for inclusion in this study were a histologic diagnosis of ovarian, fallopian tube, or primary peritoneal carcinoma and testing for *MET* nucleotide variations and/or amplification (n=178). This study was approved by the MD Anderson Institutional Review Board and patient confidentiality was maintained following Health Insurance Portability and Accountability Act guidelines.

Tissue samples and molecular analysis {#s4_2}
-------------------------------------

*MET* nucleotide variation and amplification status were tested using archival formalin-fixed, paraffin-embedded tissue blocks in addition to biologic material from fine needle aspiration biopsies or excised primary or metastatic tumors from diagnostic and/or therapeutic procedures. Histology was centrally reviewed in the MD Anderson Department of Pathology. *MET* nucleotide variations were assessed in several Clinical Laboratory Improvement Amendment-certified laboratories using a single test or as part of a gene panel. The majority of patients (n=160) were analyzed at the MD Anderson core laboratories. Of the remaining samples, 15 were tested at Knight Diagnostics (Portland, OR), 2 at the Baylor College of Medicine (Houston, TX), and 1 using a Foundation One platform (Foundation Medicine, Cambridge, MA) as previously described\[[@R13]\].

*MET* amplification status was analyzed via fluorescence in situ hybridization (FISH) following institutional protocols at MD Anderson. Copy numbers were expressed as a gene copy number in relation to *CEP7*, a gene located near the centrosome of the same chromosome. Gene copy numbers of 2-fold or greater were considered amplified.

Treatment and evaluation {#s4_3}
------------------------

All patients were enrolled when possible in a Phase I clinical trial(s) judged to be clinically appropriate by the patient\'s attending physician. Because confidentiality agreements with the providing pharmaceutical company stipulate that c-Met inhibitor identities cannot be disclosed, c-Met agents were classified as being in one of three categories: c-Met-specific inhibitor (3 separate trials), c-Met inhibitor with multikinase activity (2 separate trials), and c-Met inhibitor with multikinase kinase activity in combination with a VEGFR2 kinase inhibitor (1 trial). All c-Met inhibitors with multikinase activity also targeted the VEGFR2 receptor, a molecule associated with known clinical efficacy in ovarian cancer\[[@R14]\]. Patients were treated until clinical or radiologic disease progression, development of unacceptable toxicities or death, clinical judgment necessitating patient removal, or withdrawal of patient consent.

Clinical assessments were performed according to the specific requirements of individual protocols, typically once prior to the initiation of treatment and then at least every treatment cycle. Treatment responses were primarily assessed using computed tomography scans, magnetic resonance imaging, and/or positron emission tomography conducted prior to therapy and every 2 cycles thereafter (6-8 weeks). Radiographs were read in the Department of Radiology at MD Anderson and reviewed by physicians in our Phase I Clinical Trials Program. Objective responses were determined according to RECSIT 1.0 or 1.1 criteria, as specified by individual protocols, and the best responses achieved were recorded\[[@R15]\].

Statistical Methods {#s4_4}
-------------------

Patient demographics and tumor molecular and histologic characteristics were summarized in relation to *MET* nucleotide variation and amplification status. Time to treatment failure (TTF) was defined as the time from the initiation of therapy to its cessation for any reason. Categorical and continuous variables, including TTF and stratification by *MET* alteration were compared utilizing Fisher\'s exact and Wilcoxon rank-sum tests, respectively. Overall survival (OS) was assessed starting from the date of the first appointment in the Phase I Clinic using Kaplan-Meier analysis with comparisons via the partial likelihood ratio test. Multivariate and univariate hazard ratios (HR) were calculated via Cox regression. Wald p-values were reported for multivariate analyses. All tests were two-sided when appropriate and considered significant at *p*\<0.05. Statistical analyses were performed using SAS version 9.3 (SAS Institute Inc., Cary, NC).
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